Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationCELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundParadoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1782 · Cited by 2,256
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517 · cited 1×
“For example, type I IFNs have been found to activate dendritic cells, to increase the cytolytic activity of macrophages and NK cells, to induce the production of IL-15, to prime T cells, to increase the survival of T cells and to increase the production of stromally derived angiostatic molecules”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 1×
“The initial report showed that IFNγ-insensitive 129/Sv mice — lacking either the IFNGR1 subunit of the IFNγ receptor or the transcription factor STAT1 (signal transducer and activator of transcription 1) — developed MCA-induced sarcomas more rapidly and 3–5-fold more frequently than did their wild-type counterpart”
BackgroundSelf-citationMarincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174 · cited 1×
“In addition, many tumours that lack expression of immunologically relevant genes that are regulated by IFNs — such as MHC molecules, TAP1 (transporter associated with antigen processing 1) and LMP2 (low-molecular-mass protein 2) — have been identifie”
BackgroundThomson, A. W. (1994) · Cited by 1,116
THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor Signaling
Bach, E. A., Aguet, M., & Schreiber, R. D. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.563 · Cited by 1,034 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Regulation of Cutaneous Malignancy by γδ T Cells
Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P., Sutton, B., Tigelaar, R. E., & Hayday, A. C. (2001) · Science · doi:10.1126/science.1063916 · Cited by 1,004
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundThe roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
Self-citationSmyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Self-citationTakaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829 · cited 1×
“, as well as sarcomas generated in mice deficient in the joining gene segment Jα281 of the T-cell receptor α-chai”
BackgroundCancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 810
Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production.
Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1697 · Cited by 780
Self-citationTripp, C. S., Wolf, S. F., & Unanue, E. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3725 · Cited by 776 · cited 1×
“IL-12 regulates the induction of IFNγ expression in both the innate and the adaptive immune compartment”
Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80047-1 · Cited by 762
Chin, Y. E., Kitagawa, M., Su, W.-C. S., You, Z.-H., Iwamoto, Y., & Fu, X.-Y. (1996) · Science · doi:10.1126/science.272.5262.719 · Cited by 696
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Self-citationCretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605 · cited 1×
“This concept evolved from the observation that tumours from immunocompetent hosts and immunodeficient hosts have different immunogenic phenotype”
BackgroundSelf-citationCellular and Humoral Aspects of the Hypersensitive States
(1959) · Pediatrics · doi:10.1542/peds.24.5.773 · Cited by 581
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., MacGregor, D., Godfrey, D. I., & Trapani, J. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.755 · Cited by 576
Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis
Street, S. E. A., Cretney, E., & Smyth, M. J. (2001) · Blood · doi:10.1182/blood.v97.1.192 · Cited by 572
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 566
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1
Carpten, J., Nupponen, N., Isaacs, S., Sood, R., Robbins, C., Xu, J., Faruque, M., Moses, T., Ewing, C., Gillanders, E., et al. (2002) · Nature Genetics · doi:10.1038/ng823 · Cited by 525
Activation of the STAT Signaling Pathway Can Cause Expression of Caspase 1 and Apoptosis
Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A., & Fu, X.-Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5328 · Cited by 521 · cited 1×
“, to promote apoptosis through effects on the expression of caspases, CD95 (also known as FAS) and TRAI”
BackgroundSOCS1 Deficiency Causes a Lymphocyte-Dependent Perinatal Lethality
Marine, J.-C., Topham, D. J., McKay, C., Wang, D., Parganas, E., Stravopodis, D., Yoshimura, A., & Ihle, J. N. (1999) · Cell · doi:10.1016/s0092-8674(00)80048-3 · Cited by 516
Decreased tumor surveillance in perforin-deficient mice.
van den Broek, M. E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1781 · Cited by 512
Prognostic significance of autoimmunity during treatment of melanoma with interferon
Krauze, M. T., Tarhini, A., Gogas, H., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5023.841 · Cited by 505
Two contact regions between Stat1 and CBP/p300 in interferon γ signaling
Zhang, J. J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C. M., & Darnell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15092 · Cited by 483
The Yin and Yang of type I interferon activity in bacterial infection
Decker, T., Müller, M., & Stockinger, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1684 · Cited by 468 · cited 1×
“Although type I IFNs were originally thought to be mainly antiviral agents, recent studies have shown their importance as immunomodulator”
BackgroundTakeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465 · cited 1×
“This concept evolved from the observation that tumours from immunocompetent hosts and immunodeficient hosts have different immunogenic phenotype”
BackgroundAntigen-processing machinery breakdown and tumor growth
Seliger, B., Maeurer, M. J., & Ferrone, S. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01692-3 · Cited by 459 · cited 1×
“In addition, many tumours that lack expression of immunologically relevant genes that are regulated by IFNs — such as MHC molecules, TAP1 (transporter associated with antigen processing 1) and LMP2 (low-molecular-mass protein 2) — have been identifie”
Backgroundγδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity
Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., Craft, J., & Yin, Z. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030584 · Cited by 453
Kawanishi, S., Hiraku, Y., Pinlaor, S., & Ma, N. (2006) · Biological Chemistry · doi:10.1515/bc.2006.049 · Cited by 449 · cited 1×
“Indeed, chronic inflammation has been associated with an increased risk of developing cancer, possibly in response to the chronic production of reactive oxygen and nitrogen species leading to DNA damage, tissue remodelling and, ultimately, transformatio”
BackgroundSporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445 · cited 1×
“Recently, one group reported that tumours that develop in immunocompetent mice expressing a cryptic oncogene were immunogenic and were therefore unsculpte”
BackgroundBromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., & Darnell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7673 · Cited by 422 · cited 1×
“Given the scope of this Review, it is not possible to discuss every antitumour mechanism that might be induced by IFNγ; however, some of the processes that might be important include the capacity of IFNγ to inhibit cellular proliferatio”
BackgroundSelf-citationPartial Impairment of Cytokine Responses in Tyk2-Deficient Mice
Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00054-6 · Cited by 420
IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo.
Luster, A. D., & Leder, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1057 · Cited by 407
CD4+T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8633 · Cited by 384
Self-citationNK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. (2001) · International Immunology · doi:10.1093/intimm/13.4.459 · Cited by 379 · cited 1×
“This observation was extended to primary tumorigenesis models in which mice that were challenged with MCA and treated with exogenous IL-12 formed fewer sarcomas than did control mic”
BackgroundNK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J. (2008) · International Immunology · doi:10.1093/intimm/dxn028 · Cited by 377
Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ
Street, S. E. A., Trapani, J. A., MacGregor, D., & Smyth, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020063 · Cited by 375
Crowe, N. Y., Smyth, M. J., & Godfrey, D. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020092 · Cited by 352 · cited 1×
“This concept evolved from the observation that tumours from immunocompetent hosts and immunodeficient hosts have different immunogenic phenotype”
BackgroundNKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 342
Interferon-alpha in tumor immunity and immunotherapy
Belardelli, F., Ferrantini, M., Proietti, E., & Kirkwood, J. M. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00022-3 · Cited by 337 · cited 1×
“Subsequently, similar results were obtained when type I IFNs were administered to mice with Friend leukaemia cell (FLC) tumours or AGS melanomas (which lack STAT1), or when type I IFNs were ectopically overexpressed in several tumour type”
ResultCoughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Liu, L., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80585-3 · Cited by 324
Shimoda, K., Kato, K., Aoki, K., Matsuda, T., Miyamoto, A., Shibamori, M., Yamashita, M., Numata, A., Takase, K., Kobayashi, S., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00055-8 · Cited by 319
Mechanism of the Antitumour Effect of Interferon in Mice
GRESSER, I., MAURY, C., & BROUTY-BOYÉ, D. (1972) · Nature · doi:10.1038/239167a0 · Cited by 313 · cited 1×
“In the late 1960s, it was shown that mice that were transplanted with syngeneic tumours had significantly increased survival times when treated with crude preparations of type I IFN”
BackgroundInterferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381804 · Cited by 308
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases
Casey, G., Neville, P. J., Plummer, S. J., Xiang, Y., Krumroy, L. M., Klein, E. A., Catalona, W. J., Nupponen, N., Carpten, J. D., Trent, J. M., et al. (2002) · Nature Genetics · doi:10.1038/ng1021 · Cited by 305
Xu, X., Fu, X.-Y., PLATE, J. M. D., & Chong, A. S. (1998) · PubMed · Cited by 283
PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity
Liu, B., Mink, S., Wong, K. A., Stein, N., Getman, C., Dempsey, P. W., Wu, H., & Shuai, K. (2004) · Nature Immunology · doi:10.1038/ni1104 · Cited by 271
Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells
Street, S. E. A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., & Smyth, M. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031981 · Cited by 264
Sheehan, K. C. F., Lai, K. S., Dunn, G. P., Bruce, A. T., Diamond, M. S., Heutel, J. D., Dungo-Arthur, C., Carrero, J. A., White, J. M., Hertzog, P. J., et al. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.804 · Cited by 260 · cited 1×
“Mice that had been treated with blocking monoclonal antibody specific for the type I IFN recepto”
BackgroundSelf-citationInterferon-alpha as an immunotherapeutic protein.
Brassard, D., Grace, M. J., & Bordens, R. W. (2002) · PubMed · Cited by 247
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer
Sanda, M. G., Restifo, N. P., Walsh, J. C., Kawakami, Y., Nelson, W. G., Pardoll, D. M., & Simons, J. W. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.4.280 · Cited by 235
Wong, L. H., Krauer, K. G., Hatzinisiriou, I., Estcourt, M. J., Hersey, P., Tam, N. D., Edmondson, S., Devenish, R. J., & Ralph, S. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28779 · Cited by 234
Interferon-α as an immunotherapeutic protein
Brassard, D. L., Grace, M. J., & Bordens, R. W. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.565 · Cited by 223
Beatty, G. L., & Paterson, Y. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2276 · Cited by 195
IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice
Hanada, T., Kobayashi, T., Chinen, T., Saeki, K., Takaki, H., Koga, K., Minoda, Y., Sanada, T., Yoshioka, T., Mimata, H., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060436 · Cited by 187
Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J., Tigelaar, R. E., & Hayday, A. C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021282 · Cited by 185
Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer
Enzler, T., Gillessen, S., Manis, J. P., Ferguson, D., Fleming, J., Alt, F. W., Mihm, M., & Dranoff, G. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021258 · Cited by 179 · cited 1×
“Mice deficient in both granulocyte/macrophage colony-stimulating factor (GM-CSF) and IFNγ, as well as mice deficient in these cytokines and interleukin-3 (IL-3), developed lymphoma and non-lymphoid solid cancers at a higher rate than did mice deficient in GM-CSF alone, both IL-3 and GM-CSF, or IFNγ alon”
BackgroundThe role of type I interferons in non‐viral infections
Bogdan, C., Mattner, J., & Schleicher, U. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00207.x · Cited by 178 · cited 1×
“For example, type I IFNs have been found to activate dendritic cells, to increase the cytolytic activity of macrophages and NK cells, to induce the production of IL-15, to prime T cells, to increase the survival of T cells and to increase the production of stromally derived angiostatic molecules”
BackgroundThe DNA Damage Response Arouses the Immune System
Gasser, S., & Raulet, D. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4603 · Cited by 178
Implications for RNase L in Prostate Cancer Biology
Silverman, R. H. (2003) · Biochemistry · doi:10.1021/bi027147i · Cited by 177 · cited 1×
“Another line of evidence that type I IFNs might have a role in blocking cellular transformation comes from the finding that the endoribonuclease RNaseL, which is regulated by type I IFNs, can function as a tumour suppressor in human cell”
BackgroundINCREASED SURVIVAL IN MICE INOCULATED WITH TUMOR CELLS AND TREATED WITH INTERFERON PREPARATIONS
Gresser, I., Bourali, C., Lévy, J. P., Fontaine-Brouty-Boyé, D., & Thomas, M. T. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.51 · Cited by 176 · cited 1×
“In the late 1960s, it was shown that mice that were transplanted with syngeneic tumours had significantly increased survival times when treated with crude preparations of type I IFN”
BackgroundIFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression
Dunn, G. P., Sheehan, K. C. F., Old, L. J., & Schreiber, R. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4316 · Cited by 173
Self-citationNishikawa, H., Kato, T., Tanida, K., Hiasa, A., Tawara, I., Ikeda, H., Ikarashi, Y., Wakasugi, H., Kronenberg, M., Nakayama, T., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834479100 · Cited by 168 · cited 1×
“Previous work from the same research group showed that immunization of wild-type mice with plasmids encoding specific tumour-expressed self antigens (such as DnaJ-like 2) elicits a potent T Reg -cell respons”
BackgroundThe HLA crossroad in tumor immunology
Algarra, I., Cabrera, T., & Garrido, F. (2000) · Human Immunology · doi:10.1016/s0198-8859(99)00156-1 · Cited by 159 · cited 1×
“In addition, many tumours that lack expression of immunologically relevant genes that are regulated by IFNs — such as MHC molecules, TAP1 (transporter associated with antigen processing 1) and LMP2 (low-molecular-mass protein 2) — have been identifie”
BackgroundCutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies
Zerafa, N., Westwood, J. A., Cretney, E., Mitchell, S., Waring, P., Iezzi, M., & Smyth, M. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5586 · Cited by 159
α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis
Hayakawa, Y., Rovero, S., Forni, G., & Smyth, M. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630663100 · Cited by 150
Meng, R. D., & El‐Deiry, W. S. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5073 · Cited by 150 · cited 1×
“, to promote apoptosis through effects on the expression of caspases, CD95 (also known as FAS) and TRAI”
BackgroundEffect of interleukin 12 on tumor induction by 3-methylcholanthrene.
Noguchi, Y., Jungbluth, A., Richards, E. C., & Old, L. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11798 · Cited by 142
Wheelock, Ε. F., Weinhold, K. J., & Levich, J. D. (1981) · Advances in cancer research · doi:10.1016/s0065-230x(08)60240-7 · Cited by 138
The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse
Lesinski, G. B., Anghelina, M., Zimmerer, J., Bakalakos, T., Badgwell, B., Parihar, R., Hu, Y., Becknell, B., Abood, G., Chaudhury, A. R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16603 · Cited by 137 · cited 1×
“More recently, the administration of exogenous IFNα was shown to increase the survival of wild-type C57BL/6 mice, but not of STAT1-deficient mice (which are unresponsive to IFNs), that were challenged with AGS tumour cells from a STAT1-deficient mous”
BackgroundAnergic T cells act as suppressor cellsin vitro andin vivo
Chai, J.-G., Bartok, I., Chandler, P., Vendetti, S., Antoniou, A., Dyson, J., & Lechler, R. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199902)29:02<686::aid-immu686>3.0.co;2-n · Cited by 134
Nishikawa, H., Kato, T., Tawara, I., Takemitsu, T., Saito, K., Wang, L., Ikarashi, Y., Wakasugi, H., Nakayama, T., Taniguchi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503852102 · Cited by 119
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.
Jett, J. R., Maksymiuk, A. W., Su, J. Q., Mailliard, J. A., Krook, J. E., Tschetter, L. K., Kardinal, C. G., Twito, D. I., Levitt, R., & Gerstner, J. B. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2321 · Cited by 117
Belardelli, F., Gresser, I., Maury, C., & Maunoury, M. ‐. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300621 · Cited by 111
Reid, L. M., Minato, N., Gresser, I., Holland, J. J., Kadish, A. S., & Bloom, B. R. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.2.1171 · Cited by 111
Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.
Hayashi, T., & Faustman, D. L. (2002) · PubMed · Cited by 109
Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1
Fallarino, F., & Gajewski, T. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4109 · Cited by 106
Nishikawa, H., Kato, T., Tawara, I., Ikeda, H., Kuribayashi, K., Allen, P. M., Schreiber, R. D., Old, L. J., & Shiku, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4433 · Cited by 104
Self-citationIFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors
Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M., & Schreiber, R. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.905 · Cited by 101
Self-citationDaFonseca, C. J., Shu, F., & Zhang, J. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061487598 · Cited by 100
Issues in T‐helper 1 development – resolved and unresolved
Berenson, L. S., Ota, N., & Murphy, K. M. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00208.x · Cited by 96 · cited 1×
“By contrast, the immunomodulatory activity of IFNγ has long been appreciated, and its roles in the control of host immune responses are well establishe”
BackgroundPlasmacytoid Dendritic Cells: In Search of their Niche in Immune Responses
Barchet, W., Blasius, A. L., Cella, M., & Colonna, M. (2005) · Immunologic Research · doi:10.1385/ir:32:1-3:075 · Cited by 96
Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors.
Gresser, I., Belardelli, F., Maury, C., Maunoury, M. T., & Tovey, M. G. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.6.2095 · Cited by 93 · cited 1×
“Subsequent work showed that mice that were challenged with either allogeneic or syngeneic mouse tumours showed higher tumour growth rates and significantly decreased survival times when treated with serum that contained IFN-specific antibodies than when treated with control seru”
BackgroundDecreased STAT1 Expression by Promoter Methylation in Squamous Cell Carcinogenesis
Xi, S., Dyer, K. F., Kimak, M. A., Zhang, Q. H., Gooding, W. E., Chaillet, J. R., Chai, R. L., Ferrell, R. E., Zamboni, B. A., Hunt, J. L., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj020 · Cited by 92
Expression of SOCS-1, Suppressor of Cytokine Signalling-1, in Human Melanoma
Li, Z., Metze, D., Nashan, D., Müller‐Tidow, C., Serve, H. L., Poremba, C., Luger, T. A., & Böhm, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23408.x · Cited by 90 · cited 1×
“Moreover, another study showed that overexpression of SOCS1 (suppressor of cytokine signalling 1), a negative regulator of IFN-mediated signalling, correlates with melanoma progressio”
BackgroundSpontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice
Kacha, A. K., Fallarino, F., Markiewicz, M. A., & Gajewski, T. F. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6024 · Cited by 86
STAT5 Contributes to Interferon Resistance of Melanoma Cells
Wellbrock, C., Weisser, C., Hassel, J. C., Fischer, P., Becker, J. C., Vetter, C. S., Behrmann, I., Kortylewski, M., Heinrich, P. C., & Schartl, M. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.036 · Cited by 82
Cancer dormancy: studies of the murine BCL1 lymphoma.
Uhr, J. W., Tucker, T. F., May, R. D., Siu, H., & Vitetta, E. S. (1991) · PubMed · Cited by 76
Giannopoulos, A., Constantinides, C. A., Fokaeas, E., Stravodimos, C., Giannopoulou, M., Kyroudi, A., & Gounaris, A. (2003) · PubMed · Cited by 75
Wiesenfeld, M., O'Connell, M. J., Wieand, H. S., Gonchoroff, N. J., Donohue, J. H., Fitzgibbons, R. J., Krook, J. E., Mailliard, J. A., Gerstner, J. B., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2324 · Cited by 64
Enhanced Tumor Development in Mice Lacking a Functional Type I Interferon Receptor
Picaud, S., Bardot, B., Maeyer, E. D., & Seif, I. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900252952244 · Cited by 60 · cited 1×
“Additional efforts have been made to extend these data using tumour-transplantation approaches in mice that lack the IFNAR1 subunit of the type I IFN recepto”
BackgroundEnhanced tumorigenesis in HTLV-1 Tax-transgenic mice deficient in interferon-gamma
Mitra-Kaushik, S., Harding, J., Hess, J., Schreiber, R., & Ratner, L. (2004) · Blood · doi:10.1182/blood-2004-01-0266 · Cited by 59
Self-citationDighe, A. S., Farrar, M. A., & Schreiber, R. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82246-3 · Cited by 50
Self-citationSchreiber, G., & Schreiber, R. D. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50028-4 · Cited by 23
Self-citationVahrmeijer, A. L., van der Eb, M. M., van Dierendonck, J. H., Kuppen, P. J. K., & van de Velde, C. J. �. (1998) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199804/05)14:3<202::aid-ssu3>3.0.co;2-c · Cited by 14
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
“According to the immunosurveillance hypothesis, NK cells and CTLs engage in tumor killing (via perforin, granzyme B, TRAIL or FasL dependent mechanisms), whereas Th1 (by virtue of IFNγ production) and in some instances Th17 cells (via production of IL-17A) provide important help that boosts cytotoxic immunity (Dunn et…”
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Self-citation
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.